Drew Berweger

As AI adoption accelerates, it is crucial that companies act proactively to develop risk, compliance, and ethical frameworks to ensure sustainable innovation and responsible IP use. On the current episode of Understanding IP Matters, Allison Gaul, a registered patent attorney who evaluates digital products with an eye toward intellectual property strategy, value creation, and legal risk, discusses the aggressive landscape of data acquisition by various AI entities.

Artificial intelligence (AI), viewed from an optimist’s perspective, is an accelerant for humans; a tool to handle tedious tasks that allow users to spend more time and energy on what really matters. On the current episode of Understanding IP Matters (UIPM), Eric Bear, a classically-trained actor, singer and dancer, and now a kinesthetic artist specializing in primate motion capture, discusses the interplay of creativity and technology. Bear is a successful entrepreneur, industry expert and inventor responsible for more than 100 patents.

On the current episode of Understanding IP Matters (UIPM), Ruth Vitale, Hollywood producer, founder and co-president of Paramount Classics, and president of Fine Line Features, discusses her efforts to effect U.S. legislation that would allow for site blocking, thereby strengthening the entertainment industry and protecting U.S. consumers. As the entertainment industry is a top cultural exporter in the United States, this added protection and greater retained revenue would ensure this status continues and grows.

The value of intellectual property (IP) rights has decreased in the United States over the past 20 years because large tech companies consider patents and copyrights an enemy, not an ally, and because of the difficulty SMEs and independent creators have generating sufficient economic return. But when different stakeholder groups come together, they can develop an equitable and inclusive IP system that moves society forward while supporting their respective business agendas. These are the beliefs of Daryl Lim, a leader in understanding the global IP community.

The U.S. patent system is facing challenges from many stakeholders, including from groups that believe a weak patent system will result in lower drug prices and more widely available treatments. Such a system would have the opposite effect: fewer treatments being developed due to less research dollars spent. Research and development, and subsequently new drug products, will not occur without a meaningful patent system to provide a level of certainty that investments can be recovered.